What's Happening?
Precure, a new initiative launched by the Mayo Clinic and founding partner Thermo Fisher Scientific, has selected Helix as its multiomics laboratory and AI tools provider. This collaboration aims to generate molecular data from approximately one million
biospecimens to accelerate the integration of molecular insights into routine clinical care at the Mayo Clinic and other health systems. Helix will provide advanced AI tools for delivering genomics into the clinic and biomarker-driven research, alongside population-scale multiomic capabilities, including clinical whole genome sequencing (WGS) and research-grade proteome sequencing. The objective is to create new opportunities for disease prevention, diagnosis, and treatment by linking this molecular data with longitudinal clinical information and high-performance computing infrastructure. This initiative builds upon the Mayo Clinic's Tapestry study, which utilized Helix's Exome+ sequencing technology with 100,000 participants.
Why It's Important?
This partnership is significant for the U.S. healthcare industry as it aims to transform how the life sciences community understands biological changes preceding disease symptoms. By integrating molecular insights into clinical care on a large scale, Precure and Helix seek to enable earlier disease detection and intervention, potentially improving patient outcomes and reducing healthcare costs. The use of whole genome sequencing and multiomics as a foundation of care represents a major step towards personalized medicine, allowing for more precise and tailored treatments. This initiative could also foster the development of new biomarkers and therapeutic targets, driving innovation in the pharmaceutical and biotechnology sectors. The involvement of the Mayo Clinic, a leading U.S. medical institution, and Thermo Fisher Scientific, a major scientific instrumentation company, underscores the potential impact and credibility of this endeavor, attracting further investment and research in genomic medicine.
What's Next?
Precure and Helix plan to generate genomic data for WGS and read-out for proteomics at scale, utilizing Ultima Genomics’ UG200™ Ultra Sequencing Platform. This large-scale data generation will be crucial for building a comprehensive resource for discovery and informing patient care. The collaboration will continue to leverage Helix’s expertise in workflow orchestration, genomic sequencing, data infrastructure, and AI tools to support health system partners. As Helix is also a minority owner in Precure, any financial returns to the Mayo Clinic will be reinvested into its mission of patient care, research, and education, ensuring a sustained focus on advancing medical knowledge. The long-term goal is to establish the genome as an enduring patient resource, providing a precision baseline for a lifetime of care, which suggests ongoing efforts to integrate genomic information into routine medical practice.
Beyond the Headlines
This initiative has broader implications for data privacy, ethical considerations in genomic data usage, and the equitable access to advanced medical technologies. The collection and analysis of molecular data from one million biospecimens raise questions about data security and patient consent, necessitating robust ethical frameworks. As genomic insights become more central to healthcare, ensuring that these advancements are accessible to all segments of the U.S. population, regardless of socioeconomic status, will be a critical challenge. This collaboration could also set a precedent for how academic medical centers, technology companies, and industry partners can work together to accelerate medical innovation, potentially influencing future models of research and development in the U.S. The emphasis on preventing disease before symptoms appear could lead to a paradigm shift in healthcare, moving from reactive treatment to proactive, personalized prevention strategies.
